NASDAQ:RAPT Rapt Therapeutics Q4 2024 Earnings Report ProfileEarnings HistoryForecast Rapt Therapeutics EPS ResultsActual EPS-$9.12Consensus EPS -$3.60Beat/MissMissed by -$5.52One Year Ago EPSN/ARapt Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARapt Therapeutics Announcement DetailsQuarterQ4 2024Date3/6/2025TimeBefore Market OpensConference Call DateThursday, March 6, 2025Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Rapt Therapeutics Earnings HeadlinesThis Biotech Was Quietly Bought Before a $58 Per Share TakeoutMarch 21, 2026 | fool.comRAPT Therapeutics Completes Acquisition and Transitions to Private OwnershipMarch 18, 2026 | theglobeandmail.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.July 4 at 1:00 AM | Porter & Company (Ad)This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per ShareMarch 15, 2026 | fool.comGSK RAPT Acquisition Adds Food Allergy Asset To Immunology Growth StoryMarch 7, 2026 | finance.yahoo.comGSK reached out to buyout target's big shareholder before talking to senior leadersMarch 5, 2026 | bizjournals.comSee More Rapt Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rapt Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rapt Therapeutics and other key companies, straight to your email. Email Address About Rapt TherapeuticsRapt Therapeutics (NASDAQ:RAPT), Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies. The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma. By selectively blocking CCR4-mediated migration of pathogenic T cells to inflamed tissues, RPT193 aims to reduce disease activity without broad immunosuppression. RAPT is also advancing discovery-stage programs against additional chemokine receptors involved in tissue inflammation, including efforts in ulcerative colitis and other indications. Since its initial public offering in 2020, RAPT has expanded its operations across the United States, leveraging partnerships and collaborations to extend its global reach. The company maintains research and development facilities in San Diego and engages with clinical sites worldwide to advance its pipeline. Under the leadership of Chief Executive Officer John C. Huggins, RAPT’s management team brings extensive experience in immunology, drug discovery and clinical development. The organization is guided by a board of directors and scientific advisors with deep expertise in translational research and biopharmaceutical innovation.View Rapt Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 06/29 - 07/03Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price TargetsIs the Memory Rally Still Alive After the Semiconductor Sell-Off?Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
